High Innovation-Cost Makes Cancer Drugs Dear: A Fragile Argument?

Cancer is a major cause of high morbidity and mortality in India, just many other countries, according to a report of the World Health Organization (W.H.O). While deaths from cancer worldwide are projected to continue to rise to over 1.31 … Continue reading

Does Drug Pricing Freedom Benefit Patients in A Free-Market Economy?

A 2010 USFDA update titled ‘Generic Competition and Drug Prices’ highlighted that generic competition is intimately associated with lower drug prices, and the entry of the second generic competitor is associated with the largest price reduction. The agency found that … Continue reading

Higher The Healthcare Spend, Better The Healthcare Performance: A Myth?

It is generally believed, higher the per-capita expenditure of healthcare, better is the overall ‘healthcare performance’ of a nation. However, this myth has recently been busted by a new study, the take-home message of which would be quite relevant for … Continue reading

Regulatory Data Protection (RDP) and its need in India: The Myth versus Reality

THE MYTH: An attempt to delay the launch of Indian generics: Some in India feel that Regulatory Data Protection (RDP), is a deliberate attempt by the innovator companies to delay the launch of the generic equivalent of patented products in … Continue reading

Regulatory Data Protection (RDP) and its need in India: The Myth versus Reality

THE MYTH: An attempt to delay the launch of Indian generics: Some in India feel that Regulatory Data Protection (RDP), is a deliberate attempt by the innovator companies to delay the launch of the generic equivalent of patented products in … Continue reading